|
Study of blood factors before and after the injection of two doses of Sinopharm vaccine by review the files of Havanirooz employees
|
Sheida Kolahi Jahromi Kolahi Jahromi   , Gholam Ali Jelodar , Yousha Mahmoodi |
|
|
|
Abstract: (243 Views) |
Introduction: Coronavirus is a large family of viruses and the sub-category of Coronaviridae, which includes from the common cold virus to more severe diseases such as SARS, MERS and COVID-19. Symptoms of COVID-19 usually appear a few days after a person is infected with the virus or a little later. Symptoms can include fever, dry cough, and shortness of breath. In addition to these clinical symptoms, after exposure to the virus, a series of blood factors also change. Sinopharm is the sixth vaccine approved by the World Health Organization (WHO) for emergency use. The Sinopharm vaccine contains the SARS-CoV-2 virus, which is weakened by contact with a chemical called Beta-Propiolactone and no longer has the pathogenic power. The purpose of this study is to investigate the blood factors before and after the injection of two doses of Sinopharm vaccine.
Materials and Methods: In this study, since Havanirooz employees have to perform blood factor tests every year, the biochemical test files of 30 people with an age range of 28 to 47 years, before and after the Sinopharm vaccine injection, were examined. The investigated factors included red blood cells, hemoglobin, hematocrit, platelets, neutrophils, lymphocytes, monocytes, eosinophils, fasting blood sugar, triglycerides, and cholesterol.
Results: The results indicate that the intervention has been able to increase the amount of white blood cells, platelets, neutrophils and triglycerides on average and reduce other variables on average. The increase in neutrophils and decrease in lymphocytes was statistically significant.
Conclusion: Based on the results of this study, injection of two doses of the Sinopharm vaccine increases neutrophils and decreases lymphocytes in people who received this vaccine. Of course, it is better to study with a larger population and perform additional tests.
|
|
| Keywords: Sinopharm vaccine, COVID-19, blood factors |
|
|
Full-Text [PDF 258 kb]
(36 Downloads)
|
Type of Study: Research |
Subject:
General
Received: 2024/02/6 | Accepted: 2023/08/23 | Published: 2023/08/23
|
|
|
|
|
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
